Cargando…

Niclosamide Triggers Non-Canonical LC3 Lipidation

Autophagy is a highly- evolutionarily-conserved catabolic pathway activated by various cellular stresses. Recently, non-canonical autophagy (NCA), which does not require all of the ATG proteins to form autophagosome or autophagosome-like structures, has been found in various conditions. Moreover, mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yajun, Luo, Xia, Shan, Hao, Fu, Yuanyuan, Gu, Qianqian, Zheng, Xueping, Dai, Qi, Xia, Fan, Zheng, Zhihua, Liu, Peiqing, Yin, Xiao-Ming, Hong, Liang, Li, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468753/
https://www.ncbi.nlm.nih.gov/pubmed/30875964
http://dx.doi.org/10.3390/cells8030248
_version_ 1783411506047614976
author Liu, Yajun
Luo, Xia
Shan, Hao
Fu, Yuanyuan
Gu, Qianqian
Zheng, Xueping
Dai, Qi
Xia, Fan
Zheng, Zhihua
Liu, Peiqing
Yin, Xiao-Ming
Hong, Liang
Li, Min
author_facet Liu, Yajun
Luo, Xia
Shan, Hao
Fu, Yuanyuan
Gu, Qianqian
Zheng, Xueping
Dai, Qi
Xia, Fan
Zheng, Zhihua
Liu, Peiqing
Yin, Xiao-Ming
Hong, Liang
Li, Min
author_sort Liu, Yajun
collection PubMed
description Autophagy is a highly- evolutionarily-conserved catabolic pathway activated by various cellular stresses. Recently, non-canonical autophagy (NCA), which does not require all of the ATG proteins to form autophagosome or autophagosome-like structures, has been found in various conditions. Moreover, mounting evidence has indicated that non-canonical LC3 lipidation (NCLL) may reflect NCA. We and others have reported that niclosamide (Nic), an anti-helminthic drug approved by the Food and Drug Administration, could induce canonical autophagy via a feedback downregulation of mTOR complex 1. In this study, we found that Nic could also induce NCLL, which is independent of the ULK1 complex and Beclin 1 complex, but dependent on ubiquitin-like conjugation systems. Although bafilomycin A1 and concanamycin A, two known V-ATPase inhibitors, significantly inhibited Nic-induced NCLL, Nic-induced NCLL was demonstrated to be independent of V-ATPase. In addition, the Golgi complex and vimentin were involved in Nic-induced NCLL, which might be a platform or membrane source for Nic-induced LC3-positive structures. These results would be helpful to broaden our understanding of the working mechanisms of Nic and evaluate its pharmacological activities in diseases.
format Online
Article
Text
id pubmed-6468753
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64687532019-04-23 Niclosamide Triggers Non-Canonical LC3 Lipidation Liu, Yajun Luo, Xia Shan, Hao Fu, Yuanyuan Gu, Qianqian Zheng, Xueping Dai, Qi Xia, Fan Zheng, Zhihua Liu, Peiqing Yin, Xiao-Ming Hong, Liang Li, Min Cells Article Autophagy is a highly- evolutionarily-conserved catabolic pathway activated by various cellular stresses. Recently, non-canonical autophagy (NCA), which does not require all of the ATG proteins to form autophagosome or autophagosome-like structures, has been found in various conditions. Moreover, mounting evidence has indicated that non-canonical LC3 lipidation (NCLL) may reflect NCA. We and others have reported that niclosamide (Nic), an anti-helminthic drug approved by the Food and Drug Administration, could induce canonical autophagy via a feedback downregulation of mTOR complex 1. In this study, we found that Nic could also induce NCLL, which is independent of the ULK1 complex and Beclin 1 complex, but dependent on ubiquitin-like conjugation systems. Although bafilomycin A1 and concanamycin A, two known V-ATPase inhibitors, significantly inhibited Nic-induced NCLL, Nic-induced NCLL was demonstrated to be independent of V-ATPase. In addition, the Golgi complex and vimentin were involved in Nic-induced NCLL, which might be a platform or membrane source for Nic-induced LC3-positive structures. These results would be helpful to broaden our understanding of the working mechanisms of Nic and evaluate its pharmacological activities in diseases. MDPI 2019-03-15 /pmc/articles/PMC6468753/ /pubmed/30875964 http://dx.doi.org/10.3390/cells8030248 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Yajun
Luo, Xia
Shan, Hao
Fu, Yuanyuan
Gu, Qianqian
Zheng, Xueping
Dai, Qi
Xia, Fan
Zheng, Zhihua
Liu, Peiqing
Yin, Xiao-Ming
Hong, Liang
Li, Min
Niclosamide Triggers Non-Canonical LC3 Lipidation
title Niclosamide Triggers Non-Canonical LC3 Lipidation
title_full Niclosamide Triggers Non-Canonical LC3 Lipidation
title_fullStr Niclosamide Triggers Non-Canonical LC3 Lipidation
title_full_unstemmed Niclosamide Triggers Non-Canonical LC3 Lipidation
title_short Niclosamide Triggers Non-Canonical LC3 Lipidation
title_sort niclosamide triggers non-canonical lc3 lipidation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468753/
https://www.ncbi.nlm.nih.gov/pubmed/30875964
http://dx.doi.org/10.3390/cells8030248
work_keys_str_mv AT liuyajun niclosamidetriggersnoncanonicallc3lipidation
AT luoxia niclosamidetriggersnoncanonicallc3lipidation
AT shanhao niclosamidetriggersnoncanonicallc3lipidation
AT fuyuanyuan niclosamidetriggersnoncanonicallc3lipidation
AT guqianqian niclosamidetriggersnoncanonicallc3lipidation
AT zhengxueping niclosamidetriggersnoncanonicallc3lipidation
AT daiqi niclosamidetriggersnoncanonicallc3lipidation
AT xiafan niclosamidetriggersnoncanonicallc3lipidation
AT zhengzhihua niclosamidetriggersnoncanonicallc3lipidation
AT liupeiqing niclosamidetriggersnoncanonicallc3lipidation
AT yinxiaoming niclosamidetriggersnoncanonicallc3lipidation
AT hongliang niclosamidetriggersnoncanonicallc3lipidation
AT limin niclosamidetriggersnoncanonicallc3lipidation